Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Peginterferon · 1 trial · 1 indication
PFS was defined as response duration while on maintenance therapy. It was the length of time during and after treatment in which a participant was living with the cancer that did not get worse. PFS was calculated from the date of randomization to the date of the first documented tumor progression or relapse.
| Arm | Type | Description |
|---|---|---|
| Peginterferon α-2b | EXPERIMENTAL | Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years. |
| No Treatment | NO_INTERVENTION | Participants will be observed and will receive no treatment. |
| Name | Type | Description |
|---|---|---|
| Peginterferon | DRUG | Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years. |
Inclusion Criteria: * Must demonstrate willingness to participate in the study and to adhere to dose and visit schedules * Must be ≤85 years of age of either sex, and any race * Must have stage II or III multiple myeloma with a histological confirmation consistent with the diagnosis of multiple my...
Top 20 of 25 competitors
Peginterferon is an investigational small molecule being studied as a maintenance therapy for participants with Multiple Myeloma who responded to induction therapy. It is currently in Phase 3 clinical development, though the single completed trial did not lead to an approved indication.
Peginterferon is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company sponsored a Phase 3 clinical trial of the drug as a maintenance treatment for Multiple Myeloma.
Peginterferon is in Phase 3 clinical development for Multiple Myeloma. The Phase 3 trial has been completed, but the drug remains investigational and has not been approved by regulatory authorities for this indication.
Peginterferon has one completed Phase 3 trial, NCT00732641, titled "Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)." The trial enrolled 244 participants aged 18 years and older.
Peginterferon is not FDA approved for Multiple Myeloma. It is an investigational drug that completed a Phase 3 clinical trial, but no approval status has been established, and it remains in clinical development.